Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Company Overview - Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [3] - The company aims to deliver differentiated medicines that restore CFTR function to near-normal levels by stabilizing CFTR's nucleotide binding domain 1 (NBD1), which is believed to be crucial for improving clinical outcomes and quality of life for CF patients [3] - Sionna is advancing a pipeline of small molecules designed to correct defects caused by the F508del genetic mutation in NBD1 and is also developing complementary CFTR modulators to enhance CFTR function synergistically [3] Upcoming Events - Management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 2:00 p.m. ET [1] - A live webcast of the presentation will be available on Sionna's Investor Relations website, with a replay accessible after the event [2]